Abstract
Tumors are complex tissues composed of different cell types that interact with one another by building up complicated intra-and intercellular signal networks. In addition to the proliferating cancer cells, tumors also contain normal cells which are recruited and eroded by cancer cells to form tumor-supportive stroma and these natively normal stromal cells actively participate in the tumor development and progression by editing some of the behaviors of cancer cells and creating a tumor microenvironment to foster the rapid growth and proliferation of cancer cells. Therefore, the genetically mutated cancer cells are the cell of origin and driving forces for tumor development and progression. Selectively targeting cancer cells to induce tumor cell death and intercepting or normalizing the interaction signal network between the cancer and stromal cells are the bases for current cancer therapies. Identification of the mutated components in the intrinsic and extrinsic apoptotic pathways in cancer cells and designing small molecule mimetics or agonists to eradicate cancer cells by selectively targeting these mutations represent the attractive strategies for modern cancer therapy.
Keywords: Apoptosis, chemotherapy, TRAIL, p53, BAX, cancer drug targets, drug resistance.
Current Cancer Therapy Reviews
Title:Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Volume: 10 Issue: 1
Author(s): Shulin Wang
Affiliation:
Keywords: Apoptosis, chemotherapy, TRAIL, p53, BAX, cancer drug targets, drug resistance.
Abstract: Tumors are complex tissues composed of different cell types that interact with one another by building up complicated intra-and intercellular signal networks. In addition to the proliferating cancer cells, tumors also contain normal cells which are recruited and eroded by cancer cells to form tumor-supportive stroma and these natively normal stromal cells actively participate in the tumor development and progression by editing some of the behaviors of cancer cells and creating a tumor microenvironment to foster the rapid growth and proliferation of cancer cells. Therefore, the genetically mutated cancer cells are the cell of origin and driving forces for tumor development and progression. Selectively targeting cancer cells to induce tumor cell death and intercepting or normalizing the interaction signal network between the cancer and stromal cells are the bases for current cancer therapies. Identification of the mutated components in the intrinsic and extrinsic apoptotic pathways in cancer cells and designing small molecule mimetics or agonists to eradicate cancer cells by selectively targeting these mutations represent the attractive strategies for modern cancer therapy.
Export Options
About this article
Cite this article as:
Wang Shulin, Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152332
DOI https://dx.doi.org/10.2174/157339471001140815152332 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Opioids Resistance in Chronic Pain Management
Current Neuropharmacology Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy
Current Pharmaceutical Design Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development
Current Drug Targets Subject Index To Volume 2
Current Nutrition & Food Science Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands
Current Drug Discovery Technologies The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics